This AMEERA-2 study aimed to evaluate the safety profile, pharmacokinetics (PK), efficacy, and biomarkers, of amcenestrant, administered orally as a monotherapy with dose escalation, to Japanese postmenopausal women with advanced ER + /HER2 − breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.